Table 5.
Major differences between GR2 and PROMISSE [9] studies
| GR2 | PROMISSE [9] | |
|---|---|---|
| Time frame | 2014–2019 | 2003–2012 |
| Exclusion criteria | Twin pregnancy | Twin pregnancy UPCR >1000 mg/g Creatinine level >1.2 mg/dl Prednisone >20 mg/d |
| Ethnicity (African descent/Black) | 12.3% | 20.3% |
| History of thrombosis | 17.2% | 8.1% |
| Positive LA | 17.7% | 8.8% |
| At least one positive aPL | 26.3% | 12.5% |
| Previous renal involvement | 28.2% | 20.5% |
| HCQ exposure | 98.3% | 64.7% |
| Mean SLEPDAI at 1st trimester | 1.96 | 2.79 |
aPL: anti-phospholipid; LA: lupus anticoagulant; HCQ: hydroxychloroquine; SLEPDAI: SLE Pregnancy Disease Activity Index; UPCR: urinary protein creatinine ratio.